Nicole Rubin
Family Medicine · Oklahoma City, OKNPI 1265926059
Payments from drug & device makers
Across 61 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$170
- Novo Nordisk$121
- AbbVie$110
- GSK$91
- Lilly USA, LLC$91
- Biogen$60
- plus $311 from 14 others
What the payments were for
- Food & beverage$954100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 11 | $170 |
| Novo Nordisk | 8 | $121 |
| AbbVie | 7 | $110 |
| GSK | 6 | $91 |
| Lilly USA, LLC | 6 | $91 |
| Biogen | 4 | $60 |
| Amgen | 3 | $42 |
| Nabriva Therapeutics, PLC | 2 | $34 |
| AstraZeneca | 2 | $32 |
| Merck | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Exact Sciences | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$954 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,531 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,394 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $814 |
| Atorvastatin Calcium | 69 | $781 |
| Rosuvastatin Calcium | 23 | $731 |
| Fluoxetine Hcl | 20 | $523 |
| Omeprazole | 21 | $442 |
| Gabapentin | 33 | $429 |
| Levothyroxine Sodium | 42 | $310 |
| Pantoprazole Sodium | 26 | $295 |
| Bupropion XlBupropion Hcl | 14 | $275 |
| Lisinopril | 41 | $270 |
| Fluticasone Propionate | 24 | $249 |
| Amlodipine Besylate | 29 | $163 |
| Trazodone Hcl | 11 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $91 | $16,53121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Oklahoma City
- Carl GriffinOklahoma City$28.2M
- Alexander FrankOklahoma City$3.1M
- Charles LunnOklahoma City$1.4M
- Hieu NguyenOklahoma City$238K
- Melinda CailOklahoma City$122K
- Jose Maria Borrego AcostaOklahoma City$106K
- Brett CauthenOklahoma City$77K
- Angelique BarretoOklahoma City$74K
- John PittmanOklahoma City$39K
- Terrence TruongOklahoma City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.